Skip to content

Cardiovascular–kidney–metabolic syndrome

The 2026 AHA/ACC/ADA/ASN guideline is the first to manage obesity, diabetes, CKD and cardiovascular disease as one syndrome, staged 0–4.

AHA/ACC/ADA/ASN 2026

International Current

2026 AHA/ACC/ADA/ASN Guideline for the Management of Cardiovascular-Kidney-Metabolic Syndrome

Official source

Clinical pearls

  • Stage 1 adiposity, 2 metabolic risk factors or CKD, 3 subclinical CVD (CAC ≥100, pre-HF), 4 clinical CVD.
  • SGLT2i and GLP-1-based therapy are the backbone across stages.
  • CKD: RASi → SGLT2i → finerenone → GLP-1 RA.